Webinar: On-target development, July 2020 : Retrogenix

Off-Target Screening: Webinar

Specificity screening of biotherapeutics

Ensuring that a novel biotherapeutic is specific to its intended target is undoubtedly advantageous when selecting promising lead candidates, however, it becomes vital when assessing potential safety implications prior to clinical studies.

This webinar provides an overview of the Cell Microarray technology, with a particular focus on specificity/off-target screening.

Understand how data generated with Cell Microarray screening is used in lead selection and safety assessment
Explore how specificity data supports IND submissions as either an adjunct to, or replacement for, tissue cross reactivity studies
Learn more about identifying and mitigating the risk of clinical toxicity caused by off-target effects of monoclonal antibodies.

Featured presentations:

“True specificity is a critical development characteristic in therapeutic antibody development.”

Jonny Finlay, PhD – CEO, UltraHuman Limited

“Off-target Screening: A Pharma Industry Perspective.”

Martin Scott, PhD – Scientific Leader and Associate Fellow, GSK

“Cell Microarray technology in specificity screening.”

Nick Brown, MSc – Retrogenix Limited

Why use Retrogenix?

Our unique Cell Microarray technology identifies primary receptors and any potential secondary targets with a high degree of specificity and sensitivity, providing valuable data that can inform lead selection, assist with safety assessment and support regulatory submissions.

Retrogenix’s specificity data have been readily accepted in applications for clinical trials and marketing approval in the US (FDA), Europe (EMA), China (NMPA) & Japan (PMDA). Further details can be found in our case study using the link below. Or, to ask a question, please get in touch with a member of our team.

Retrogenix data in regulatory submissions

Get In Touch

We are very pleased with the service Retrogenix provided to us. In less than two months they were able to identify and confirm the target specificity of multiple antibodies we provided to Retrogenix (over 70% of antibodies provided).This helped us to validate our internal technology development.

Head of Antibody Discovery, Bayer

Peptinnovate Ltd - Unlocking Nature's Potential